home > news > 2008 > june > pfizer report validates use of simcyp simulator in the assessment of drug-drug interactions
Pfizer report validates use of Simcyp Simulator in the assessment of drug-drug interactions
Date: 10 Jun 2008
Scientists at Pfizer Global Research and Development (Sandwich, Kent) have used the Simcyp Simulator to successfully predict the extent of drug-drug interactions for maraviroc, which is used in combination with other medications in the treatment of HIV. The results of the research by Hyland et al. will appear in British Journal of Clinical Pharmacology.
The group used the Simcyp Simulator, together with in vitro data, to predict in vivo outcomes. The results of this ‘virtual’ study were then compared with observed clinical data. The simulations were found to be in good agreement with the clinical results, which led to the conclusion that validated models of drug-drug interactions within Simcyp allow for the prediction of other metabolic drug-drug interactions without the need for a clinical study.
The report stated: “Simcyp has successfully simulated the extent of clinical interactions with CYP3A4 inhibitors, further validating this software as a good predictor of CYP-based drug-drug interactions.”
The paper is entitled ‘Maraviroc: in vitro assessment of drug-drug interaction potential’. For a link to the abstract and full text options please click here.